Company database

ZA

Zhejiang Ausun Pharmaceutical

Compare

An API and intermediate company that also provides CDMO services. Group financials are not pure CDMO revenue.

LC

Lianhe Chemical Technology

Compare

Combines pharmaceutical CDMO with crop protection and functional chemicals; group financials do not represent the pharmaceutical CDMO segment.

C

Chemspec

Compare

Combines fine chemical materials with pharmaceutical CDMO.

J

JinKailife

Compare

A small-molecule CDMO serving pharmaceutical and life science clients.

CP

Chengda Pharmaceuticals

Compare

Combines pharmaceutical-intermediate CDMO with proprietary products such as L-carnitine.

JF

Jiangxi Fushine Pharmaceutical

Compare

The official pharmaceutical manufacturing page offers custom CDMO services. The group also operates APIs, new-energy electrolyte additives, and synthetic biology products.

ZH

Zhejiang Haisen Pharmaceutical

Compare

The website explicitly offers CMO/CDMO from process development through commercialization; a 2026 investor presentation discusses deepening CDMO. Human/veterinary APIs and intermediates remain the main businesses.

AH

Anhui Heryi Pharmaceutical

Compare

Custom pharmaceutical-intermediate and API business; service scope must be distinguished from proprietary products.

BS

Beijing Sunho Pharmaceutical

Compare

Combines drug-product sales with CMC/CMO/CDMO services.

SO

Shanghai OPM Biosciences

Compare

Combines cell-culture media products and biologics CDMO; consolidated financials include products and acquisition effects.

OT

OBiO Technology

Compare

Gene therapy vector CRO/CDMO; platform services do not represent the clinical stage of a proprietary candidate.

G

GemPharmatech

Compare

Animal models, breeding, and pharmacology/efficacy services, at the intersection of preclinical tools and outsourced services.

Animal-model products, custom models, and efficacy evaluation services; distinct from clinical CRO.

BP

BLD Pharmatech

Compare

The annual report describes product supply plus custom development, designing molecular structures and synthetic routes around customer targets. Primarily a molecular building-block supplier; included as adjacent to drug-discovery services.

NS

Novoprotein Scientific

Compare

Combines recombinant proteins and molecular reagents with custom R&D and CDMO. Products and outsourced services must be distinguished.

SB

Sino Biological

Compare

Combines biological reagent products with protein/antibody custom research CRO services.

CT

Centre Testing International

Compare

A diversified testing group with pharmaceutical CRO/bioanalysis operations. Total group revenue must not be presented as pharmaceutical outsourcing revenue.

PT

PONY Testing International

Compare

A diversified testing group including pharmaceutical testing/CRO; financials cover all testing businesses.

BI

BioDlink International (formerly TOT BIOPHARM)

Compare

Formerly TOT BIOPHARM, now BioDlink, combining CDMO/CMO and proprietary oncology products. Controlled by WuXi XDC in 2026 but still reporting as an HKEX-listed entity.

MI

Medtide Inc.

Compare

The HKEX 2025 annual report confirms integrated synthetic peptide and oligonucleotide CRDMO. Listed on 2025-06-30.

WH

Wuhan Hiteck Biological Pharma

Compare

Combines biologic drug products and subsidiary small-molecule CDMO/CMC services. Group losses cannot be attributed solely to CDMO.

HT

Henan Taloph Pharmaceutical

Compare

Combines traditional Chinese medicine manufacturing and outsourced pharmaceutical R&D. The current consolidation status of subsidiaries such as New Leading must be checked.

SS

Shanghai Sinotherapeutics

Compare

Combines proprietary generics with advanced drug-product CDMO services.

Combines complex APIs, drug products, and innovative drugs with technology transfer and R&D technical services. Contract fees include helping clients complete development and obtain approvals; included as an adjacent diversified R&D service business, not a pure contract CDMO.